Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy

Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy

Presented By
Dr Marta Casarrubios, Hospital Puerta de Hierro-Majadahonda, Spain
Conference
ELCC 2022
Trial
Phase 2, NADIM
Doi
https://doi.org/10.55788/31c26acb
In the phase 2 NADIM trial, upregulated expression of genes involved in type II interferon signalling as well as the presence of M1 macrophages, follicular helper T cells, activated NK cells, and resting dendritic cells in the tumour predict complete pathological response to neoadjuvant chemoimmunotherapy in patients with stage IIIA non-small cell lung cancer (NSCLC). Neoadjuvant chemoimmunotherapy is increasingly explored as a treatment option for patients with NSCLC. Recently, the open-label, single-arm, phase 2 NADIM trial (NCT03081689) demonstrated improved outcomes with nivolumab plus paclitaxel/carboplatin chemotherapy for patients with stage IIIA NSCLC; 82.9% of participants achieved a major pathological response (>90% necrosis), and 63.4% of participants achieved a complete pathological response (100% necrosis) [1]. In a post-hoc analysis, gene expressi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on